Chronic Lymphocytic Leukemia: Diagnosis, Treatment Options and Prognosis

Kimberly Rodriquez (Editor)

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED088000

Clear

$160.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Browse Wishlist
Browse Wishlist

Details

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in the western world, seen mostly in the elderly age-group and has a very variable clinical outcome. Traditionally considered an indolent, antigen inexperienced leukemia of slowly accumulating cells that do not die, researchers now acknowledge that CLL cells are highly proliferative, antigen experienced cells that have a high cell turnover and a subset show an aggressive clinical course. The onset of the disease is usually asymptomatic; only abnormalities in whole blood count such as leukocytosis with lymphocytosis are found. Nowadays, CLL is diagnosed more often at an early, asymptomatic stage due to more frequent routine blood tests. More advanced stages are characterized by lymphadenopathy, hepatomegaly/splenomegaly, recurrent infections, weakness, pallor and hemorrhagic diathesis, and general symptoms such as weight loss, fever and night sweats are observed. This book reviews the diagnosis, treatment options and prognosis of CLL. (Imprint: Nova Biomedical)

Preface

Chapter 1. The Chemokine Receptor CCR3 in Chronic Lymphocitic Leukemia: Possible Biological Role in the Course of the Disease
Vladimirova R., Vikentieva E., Popova D., Gigov I., Raynov J., Mihova A., and Guenova M. (Military Medical Academy, Sofia, Bulgaria, and others)

Chapter 2. New and Repositioning Approaches to the Treatment of Chronic Lymphocytic Leukemia
Ida Franiak-Pietryga and Maria Bryszewska (Department of Clinical and Laboratory Genetics, Medical University of Lodz, Poland, and others)

Chapter 3. Prognostic and Predictive indicators in Chronic Lymphocytic Leukemia
Nili Saar, Pia Raanani and Uri Rozovski (Division of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel, and others)

Chapter 4. Molecular Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia: Prognostic Implication
Prabhjot Kaur (Associate Professsor of Pathology, Department of Pathology, Dartmouth Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH, USA)

Index

You have not viewed any product yet.